What methods are used to study neurobiological effects of ADHD medications?

No single method can show both what a medication does in the brain and what it does for a person

Understanding an ADHD medication means answering questions at very different scales. Which molecules does it bind to, and how tightly? Which brain regions change their activity when it is taken? Does attention or impulse control measurably change on a task? Do symptoms improve in a clinical trial? And what happens to people who take it for years? Each question needs its own tools, and the strength of the evidence behind Canadian treatment guidelines comes from the fact that the answers from different methods line up.

The methods below are listed roughly from the most basic biological level to the most real-world. Researchers describe this as moving from mechanism to outcome. A reader who wants the plain-language version of what the medications do can start with the blog post on how ADHD medications work on the brain; this page is about how that knowledge was produced.

Laboratory and animal studies establish the mechanism before any human study

The first layer of evidence comes from the bench. Receptor-binding assays measure how strongly a compound attaches to specific targets, such as the dopamine and norepinephrine transporters, and whether it blocks them, reverses them or stimulates a receptor directly. Microdialysis in animal models measures the actual rise in neurotransmitter levels in specific brain regions after a dose. Behavioural tests in animals, including tasks that reward waiting or sustained responding, give an early read on whether a mechanism translates into changes in impulsivity or attention.

Animal models of ADHD, such as rat strains bred for hyperactivity and inattention, let researchers test developmental questions that cannot be studied in people, for example what long-term exposure during adolescence does to the developing brain. Their limitation is obvious: no animal has ADHD as the DSM-5-TR defines it, so these studies inform hypotheses rather than settle clinical questions.

Imaging methods show where a medication acts and how brain activity changes in people

Human neuroimaging bridges the gap between mechanism and behaviour. Each technology answers a different part of the question, and medication studies commonly scan the same people on and off treatment so that each person serves as their own comparison.

Imaging studies tend to be small because scanning is expensive, so their findings are most trustworthy when pooled across sites or replicated. They explain how a medication works far better than they predict who will benefit.

Neuropsychological tasks and randomized trials measure what the medication does for attention and symptoms

The next layer measures performance and symptoms rather than brain signals. Neuropsychological tasks give objective, repeatable readouts, while randomized controlled trials are the evidence regulators and guidelines weigh most heavily.

• Continuous performance tests. Long, monotonous computer tasks that measure sustained attention, reaction-time variability and errors of commission, all of which are sensitive to medication.
• Stop-signal and go/no-go tasks. Measure the ability to cancel a response already under way, a laboratory proxy for impulsivity.
• Working memory and delay-discounting tasks. Test how much information can be held in mind and how strongly a person prefers smaller immediate rewards over larger delayed ones.
• Randomized, double-blind, placebo-controlled trials. Participants are assigned by chance to medication or placebo, and symptom change is measured with validated rating scales completed by the person, a parent or a clinician.
• Crossover and dose-response trials. Each participant tries several doses or several medications in random order, which shows how effects scale with dose.
• Systematic reviews and meta-analyses. Pool many trials to estimate the overall size and consistency of effects, and to compare medications that were never tested head to head.

Health Canada relies on this trial evidence when it approves a medication for ADHD, and the Canadian ADHD Resource Alliance (CADDRA) grades it when ranking treatment options in its guidelines. Trials are typically short, weeks to a few months, which is why a further layer of evidence is needed.

Registry, cohort and genetic studies answer the questions trials are too short to address

What happens over years, and what happens outside the controlled conditions of a trial, is studied with observational methods. Population registries, particularly in Scandinavian countries where prescribing and health records are linked, allow researchers to compare periods when the same person was and was not taking medication and to look at outcomes such as injuries, driving incidents and educational attainment. Long-term cohorts like the Multimodal Treatment Study of ADHD followed children into adulthood and examined growth, symptoms and functioning across treatment groups. Pharmacogenetic studies look for variants in genes related to dopamine and norepinephrine that might explain why individuals respond differently.

These designs cannot prove cause and effect the way a randomized trial can, because people who stay on medication differ from those who stop. Their value is scale and realism. The answer on what long-term outcome studies show summarizes the findings themselves.

For a patient, the practical result of all this research is structured monitoring

The methods described above feed directly into routine care. The baseline measures your prescriber records, blood pressure, heart rate, weight, sleep and mood, come from what trials and registries identified as worth tracking. The rating scales completed at follow-up are the same validated instruments used as trial outcomes. The gradual dose increases follow dose-response findings. In effect, each person's treatment is a small, careful version of the studies that established it, and the page on how ADHD medication is monitored after starting explains what that looks like in practice.

Finding Focus provides online ADHD assessment and treatment for adults and teens in several Canadian provinces, following CADDRA guidance for assessment, prescribing and follow-up. After a short online intake you have one consultation with a licensed Canadian clinician, no referral is needed, and assessments start from $399.